Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer.
Straetemans T, Gründer C, Heijhuurs S, Hol S, Slaper-Cortenbach I, Bönig H, Sebestyen Z, Kuball J. Straetemans T, et al. Among authors: grunder c. Clin Cancer Res. 2015 Sep 1;21(17):3957-68. doi: 10.1158/1078-0432.CCR-14-2860. Epub 2015 May 19. Clin Cancer Res. 2015. PMID: 25991821
γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia.
Scheper W, van Dorp S, Kersting S, Pietersma F, Lindemans C, Hol S, Heijhuurs S, Sebestyen Z, Gründer C, Marcu-Malina V, Marchant A, Donner C, Plachter B, Vermijlen D, van Baarle D, Kuball J. Scheper W, et al. Among authors: grunder c. Leukemia. 2013 Jun;27(6):1328-38. doi: 10.1038/leu.2012.374. Epub 2013 Jan 1. Leukemia. 2013. PMID: 23277330
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.
Loff S, Dietrich J, Meyer JE, Riewaldt J, Spehr J, von Bonin M, Gründer C, Swayampakula M, Franke K, Feldmann A, Bachmann M, Ehninger G, Ehninger A, Cartellieri M. Loff S, et al. Among authors: grunder c. Mol Ther Oncolytics. 2020 Apr 29;17:408-420. doi: 10.1016/j.omto.2020.04.009. eCollection 2020 Jun 26. Mol Ther Oncolytics. 2020. PMID: 32462078 Free PMC article.